Arkolith/Insider Trading/ETTX/Form 4

Wagner Kristie Ann

VP, Principal Fin & Acct OffEntasis Therapeutics Holdings Inc. (ETTX) · full profile →Form 4 · filed Jul 11, 2022
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 11, 2022Disposed to issuer(D)81K——0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 11, 2022Other(J)73K—$00

Transaction Codes

D
Disposition to the issuer
J
Other acquisition / disposition

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-22-078804) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML